World Library  
Flag as Inappropriate
Email this Article
 

Cisapride

Cisapride
Systematic (IUPAC) name
(±)-cis-4-amino-5-chloro-N-(1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl)-2-methoxybenzamide
Clinical data
Trade names Prepulsid, Propulsid
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
Legal status
Routes of
administration
oral (tablets), suspension
Pharmacokinetic data
Bioavailability 30-40%
Protein binding 97.5%
Metabolism hepatic CYP3A4, intestinal
Biological half-life 10 hours
Excretion renal, biliary
Identifiers
CAS Registry Number  Y
ATC code A03
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  N
Chemical data
Formula C23H29ClFN3O4
Molecular mass 465.945 g/mol
 N   

Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT4 receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. It has been sold under the trade names Prepulsid (Janssen-Ortho) and Propulsid (in the United States). It was discovered by Janssen Pharmaceutica in 1980. In many countries, it has been either withdrawn from the market or had its indications limited because of side-effects.

The commercial preparations of this drug are the racemic mixture of both enantiomers of the compound. The (+) enantiomer itself has the major pharmacologic effects and does not induce many of the detrimental side-effects of the mixture.[1]

Contents

  • Medical uses 1
  • Veterinary uses 2
  • Kinetics 3
  • Pharmacology and mechanism of action 4
  • See also 5
  • References 6
  • Sources 7
  • External links 8

Medical uses

Cisapride has been used for the treatment of gastroesophageal reflux disease (GERD). There is no evidence it is effective for this use in children.[2] It also increases gastric emptying in people with diabetic gastroparesis. Evidence for its use in constipation is not clear.[3]

In many countries, it has been either withdrawn or had its indications limited because of reports of the side-effect long QT syndrome, which may cause arrhythmias. The U.S. Food and Drug Administration (FDA) issued a warning letter to doctors,[4] and cisapride was voluntarily removed from the U.S. market on July 14, 2000. Its use in Europe has also been limited.[2] It was banned in India and in the Philippines in 2011.[5]

Veterinary uses

Cisapride is still available in the United States and Canada for use in animals, and is commonly prescribed by veterinarians to treat megacolon in cats.

Cisapride is also commonly used to treat GI stasis in rabbits, sometimes in conjunction with metoclopramide (Reglan).

Kinetics

Oral bioavailability of cisapride is approximately 33%. It is inactivated primarily by hepatic metabolism by CYP3A4 with a half-life of 10 hours. The dose of the drug should be reduced in case of liver diseases.[6]

Pharmacology and mechanism of action

As a prokinetic agent that increases gastrointestinal motility, cisapride acts as a selective serotonin agonist in the 5-HT 4 receptor subtype. Cisapride also relieves constipation-like symptoms by indirectly stimulating the release of acetylcholine in the muscarinic receptors.

See also

References

  1. ^ US patent 5955478, Nancy M. Gray, N. M.; Young, J. W, "Methods for treating gastrointestinal motility dysfunction using optically pre (+) cisapride", issued 1999-Sep-21 
  2. ^ a b Maclennan, S; Augood, C; Cash-Gibson, L; Logan, S; Gilbert, RE (Apr 14, 2010). "Cisapride treatment for gastro-oesophageal reflux in children.". The Cochrane database of systematic reviews (4): CD002300.  
  3. ^ Aboumarzouk, OM; Agarwal, T; Antakia, R; Shariff, U; Nelson, RL (Jan 19, 2011). "Cisapride for intestinal constipation.". The Cochrane database of systematic reviews (1): CD007780.  
  4. ^ "Propulsid (cisapride) Safety Information". Retrieved 2011-07-14. 
  5. ^ "Drugs banned in India". Central Drugs Standard Control Organization, Dte.GHS, Ministry of Health and Family Welfare, Government of India. Retrieved 2013-09-17. 
  6. ^ "Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers" European Journal of Clinical Pharmacology T Hedner et al. Volume 38, Number 6, 629-631, doi:10.1007/BF00278595

Sources

  • Brenner, G. M. (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4
  • Medline Plus

External links

  • Archived Drug Label
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.